Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net income	$ 26,590	$ 30,417
Adjustments to reconcile net income to net cash provided by operating activities:
Change in fair value of warrant liability	(2,649)	(18,609)
Depreciation and amortization	8,468	7,532
Amortization of deferred financing costs	739	2,529
Accretion of debt discount	2,862	3,963
Gain on sale of assets	(3,039)	(2,718)
Stock compensation expense	9,571	4,810
Deferred income taxes	1,018	727
Excess tax benefit related to share-based awards	(579)	(556)
Non-cash loss on extinguishment of debt	4,270	3,225
Change in current assets and liabilities:
Accounts receivable, net	532	(19,146)
Inventories	(4,287)	(8,470)
Other current assets	(2,213)	(1,177)
Accounts payable	808	2,840
Accrued liabilities	1,092	(5)
Income taxes payable	(2,993)	4,187
Interest payable	(1,733)	(1,427)
Net cash provided by operating activities	38,457	8,122
Cash flows from investing activities:
Capital expenditures	(15,243)	(5,971)
Proceeds from sale of assets	3,376	3,765
Purchase of patents and other intangible assets	(31)	(243)
Net cash used in investing activities	(11,898)	(2,449)
Cash flows from financing activities:
Repayments of indebtedness	(51,828)	(33,081)
Excess tax benefit related to share-based awards	579	556
Purchase of treasury stock	(497)	(205)
Proceeds from sale of common stock		29,438
Proceeds from exercise of stock options	167	136
Proceeds from exercise of warrants	263	4,581
Debt issuance costs		(1,346)
Net cash (used in) provided by financing activities	(51,316)	79
Effect of changes in exchange rates on cash and cash equivalents	16	(120)
Net (decrease) increase in cash and cash equivalents	(24,773)	5,632
Cash and cash equivalents at the beginning of period	46,682	19,863
Cash and cash equivalents at the end of period	$ 21,909	$ 25,495